Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Dementia Associated With Cerebrovascular Disease

Conditions

Dementia Associated With Cerebrovascular Disease

Trial Timeline

Aug 5, 2013 → Dec 21, 2018

NCT ID

NCT02660983

About Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride

Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride is a approved stage product being developed by Eisai for Dementia Associated With Cerebrovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02660983. Target conditions include Dementia Associated With Cerebrovascular Disease.

What happened to similar drugs?

8 of 20 similar drugs in Dementia Associated With Cerebrovascular Disease were approved

Approved (8) Terminated (1) Active (11)

✅E2020 + PlaceboEisaiApproved

✅donepezil hydrochloride (Aricept)EisaiApproved

✅MecobalaminEisaiApproved

✅Risperdal,reminylJohnson & JohnsonApproved

✅ENA713NovartisApproved

✅Rivastigmine Patch 9.5 cm2NovartisApproved

✅Memantine + PlaceboLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02660983	Approved	Completed	Aug 5, 2013	Dec 21, 2018	Dementia Associated With Cerebrovascular Disease

Competing Products

20 competing products in Dementia Associated With Cerebrovascular Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40